<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622488</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO 3-7-2</org_study_id>
    <nct_id>NCT04622488</nct_id>
  </id_info>
  <brief_title>The Effect of Diclofenac Potassium Insitu Gel Vs Calcium Hydroxide as Intra-canal Medications on Post-operative Pain and Anti-bacterial Effect</brief_title>
  <official_title>The Effect of Diclofenac Potassium Insitu Gel Versus Calcium Hydroxide as Intra-canal Medications on Post-operative Pain and Anti-bacterial Effect in Lower Non Vital Premolars With Symptomatic Apical Periodontitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to clinically compare the post-operative pain level and&#xD;
      antibacterial effect when using the Diclofenac Potassium Insitu gel versus calcium hydroxide&#xD;
      as an intra- canal medication in patients with apical periodontitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Post operative pain assessed by VAS</measure>
    <time_frame>72 hours</time_frame>
    <description>Post-operative pain following chemo-mechanical endodontic treatment will be measured.&#xD;
A pain chart using visual analogue scale (VAS) will be used to record the patients' pain levels. The VAS (0-10 scale) consists of a line anchored by two extremes &quot;No pain&quot; and &quot;the worst pain&quot;. Patients will be asked to choose the mark that represented their level of pain from 0 to 10. Pain level will be assigned as follow:&#xD;
0, &quot;no pain&quot;&#xD;
1-3, &quot;mild pain&quot;&#xD;
4-6, &quot;moderate pain&quot;&#xD;
7-10, &quot;severe pain&quot; Using the VAS chart, the patient will choose and record the most appropriate pain rating according to the pain intensity endured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibacterial effectiveness by measuring the bacterial count.</measure>
    <time_frame>pre-operatively(S1), after chemo-mechanical preparation(S2), and after 1 week(S3).</time_frame>
    <description>The bacterial count method will be used. Once the samples will arrive to the microbiology department, Cairo University, the tubes containing the thioglycolate 14(transport medium) with the paper points will be placed in micro centrifuge and vortexed for 30 sec. One hundred (100) Î¼l aliquots of the vortexed samples will be placed in a new sterile tube containing 1 ml of thioglycolate to obtain 1/10 concentration to assess the microbial load of common aerobes and anaerobes found in each root canal. The effect of the treatment in each group, the initial colonizers (S1), the mechanical preparation (S2) and after the intra-canal medication (S3) will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>Diclofenac Potassium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the form of insitu gel can be applied as solution or suspension that undergoes gelation after administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Hydroxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Potassium</intervention_name>
    <description>- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.</description>
    <arm_group_label>Calcium Hydroxide</arm_group_label>
    <arm_group_label>Diclofenac Potassium</arm_group_label>
    <other_name>Cataflam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-45 years old.&#xD;
&#xD;
          -  Males/Females.&#xD;
&#xD;
          -  Lower permanent premolars with: Non-Vital pulps. Sensitive to percussion. Negative&#xD;
             response to cold pulp tester (ethyl chloride spray1). Apical periodontitis&#xD;
&#xD;
          -  Systemically healthy patients (ASA I or II).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medically compromised patients having significant systemic disorders. (ASA III or IV).&#xD;
&#xD;
               -  History of intolerance to NSAIDS.&#xD;
&#xD;
               -  Patients with two or more adjacent teeth requiring endodontic treatment.&#xD;
&#xD;
               -  Teeth with :&#xD;
&#xD;
          -  Association with swelling or fistulous tract.&#xD;
&#xD;
          -  Acute or chronic peri-apical abscess. Mobility Grade II or III.&#xD;
&#xD;
          -  Pocket depth more than 5mm.&#xD;
&#xD;
          -  Previous root canal therapy.&#xD;
&#xD;
          -  Non-restorability&#xD;
&#xD;
          -  Patients with a contraindication for the use of DFK or those known to be allergic to&#xD;
             any of the study medications.eg. Patient with kidney problems.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heba El Far, Professor</last_name>
    <phone>+201282006589</phone>
    <email>hebaelfar@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dina Morsy, doctorate</last_name>
    <phone>+201223980157</phone>
    <email>dina.amorsy@dentistry.cu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Dentistry Cairo University</name>
      <address>
        <city>Cairo</city>
        <state>El- Manial</state>
        <zip>11553</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Heba El Far, Professor</last_name>
      <phone>+201282006589</phone>
      <email>hebaelfar@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dina Morsy, Doctorate</last_name>
      <phone>+201223980157</phone>
      <email>dina.amorsy@dentistry.cu.edu.eg</email>
    </contact_backup>
    <investigator>
      <last_name>Salma Aboul Azayam, bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Salma Mohamed Aboul Azayem</investigator_full_name>
    <investigator_title>Prinicipal Investegator</investigator_title>
  </responsible_party>
  <keyword>Calcium Hydroxide</keyword>
  <keyword>Diclofenac potassium</keyword>
  <keyword>Intra-canal Medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

